3区 · 医学
Article
作者: Packiriswamy, Nandakumar ; Narjari, Riya ; Muñoz-Alía, Miguel Á ; Zhang, Lianwen ; Recker, Jordan ; Haselton, Michelle ; Suksanpaisan, Lukkana ; Sevola, Kara ; Russell, Luke ; Sakuma, Toshie ; Graham, Melanie L ; Ziegler, Christopher ; Lee, Rachael M ; Balakrishnan, Baskar ; Russell, Stephen J ; Reiter, Samantha ; Gnanadurai, Clement ; Petro, Christopher D ; Waniger, Scott ; Vandergaast, Rianna ; Kyratsous, Christos A ; Tesfay, Mulu ; Janecek, Jody L ; Lech, Patrycja ; Carey, Timothy ; Krotova, Karina ; Baum, Alina ; Ramachandran, Sabarinathan ; Peng, Kah-Whye ; Lathrum, Chase
An orally active vaccine capable of boosting SARS-CoV-2 immune responses in previously infected or vaccinated individuals would help efforts to achieve and sustain herd immunity. Unlike mRNA-loaded lipid nanoparticles and recombinant replication-defective adenoviruses, replicating vesicular stomatitis viruses with SARS-CoV-2 spike glycoproteins (VSV-SARS2) were poorly immunogenic after intramuscular administration in clinical trials. Here, by G protein trans-complementation, we generated VSV-SARS2(+G) virions with expanded target cell tropism. Compared to parental VSV-SARS2, G-supplemented viruses were orally active in virus-naive and vaccine-primed cynomolgus macaques, powerfully boosting SARS-CoV-2 neutralizing antibody titers. Clinical testing of this oral VSV-SARS2(+G) vaccine is planned.